Publications

Uptake of moss‐derived human recombinant GAA in Gaa−/− mice

Hintze S, Dabrowska-Schlepp P, Berg B, et al. Uptake of moss-derived human recombinant GAA in Gaa−/−mice. JIMDReports. 2021;1–9.https://doi.org/10.1002/jmd2.12203.

Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease

Hintze S, Limmer S, Dabrowska-Schlepp P, Berg B, Krieghoff N, Busch A, Schaaf A, Meinke P, Schoser B. 2020. nt J Mol Sci. 2020 Apr 10;21(7):2642. doi: 10.3390/ijms21072642.

CLARIOstar® determines activity of a moss-produced human acid alphaglucosidase (GAA) in a fluorescence-based assay

Berg B, Fischer A, Haessler F, Dabrowska-Schlepp P, Maurer F, Tintelnot S. 2019. BMG LABTECH. 339: Ortenberg.

Single‐Use Processing as a Safe and Convenient Way to Develop and Manufacture Moss‐Derived Biopharmaceuticals

Niederkrueger H, Busch A, Dabrowska-Schlepp P, Krieghoff N, Schaaf A, Frischmuth T. 2019. In: Eibl R, Eibl D, editors. Single-Use Technology in Biopharmaceutical Manufacture. 2nd ed. Hoboken, NJ: Wiley. p. 311-318.

Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry disease

Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. 2019. Journal of Inherited Metabolic Disease. 42(3): Hoboken, NJ.

Real-time VCD monitoring of moss for therapeutic protein production

Koch J, Mueller M, Niederkrueger H. 2018. Hamilton. Bonaduz.

Pharmacokinetics, pharmacodynamics, and safety of moss agalactosidase A in patients with Fabry disease

Hennermann JB, Arash-Kaps L, Fekete G, Schaaf A, Busch A, Frischmuth T. 2018. 123(2): Cambridge.

Treatment of experimental C3 Glomerulopathy by human complement factor H produced in glycosylation-optimized Physcomitrella patens

Haeffner K, Parsons J, Bohlender L, Hoernstein S, Niederkrueger H, Fode B, Busch A, Krieghoff N, Koch J, Schaaf A, Frischmuth T, Zipfel P, Pohl M, Reski R, Decker E, Michelfelder S. 2017. Molecular Immunology. 89: Oxford.